Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
Volume 48, Issue -, Pages 425-461Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.pharmtox.48.113006.094847
Keywords
coreceptor; CCR5; therapy; prevention; microbicide; resistance
Categories
Funding
- NIAID NIH HHS [R01 AI 41420, P01 AI 51649, R21 AI 071935] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI071935, R01AI041420, P01AI051649] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Since the identification of CCR5 and CXCR4 as HIV coreceptors a little over a decade ago, there has been hope that coreceptor inhibitors will be able to make an impact on the HIV epidemic, both as novel therapeutic drugs and as agents used in prevention. Significant progress has been made in the understanding of how coreceptor choice might impact HIV pathology and how coreceptor blockade may affect health. In this review, we focus on some of the key issues that are emerging now that CCR5 has been validated as a promising target for HIV prevention strategies and at a time when a CCR5 inhibitor has been approved in the United States as the first in a new class of anti-HIV therapeutic drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available